

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

PROPOSED INVESTMENT IN PT INDO GENESIS MEDIKA – SUPPLEMENTAL LETTER TO THE MOU

1. INTRODUCTION

- 1.1 The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") refers to the announcement dated 23 August 2018 ("**23 Aug 2018 Announcement**") in relation to the Proposed Investment. Unless otherwise defined, all capitalised terms used in this announcement shall have the same meaning and construction in the 23 Aug 2018 Announcement.
- 1.2 The Board wishes to announce that the Company's wholly-owned subsidiary, SAM Laboratory Pte. Ltd., has today entered into a supplemental letter to the MOU with PT Indo Genesis Medika and KPN:
- (a) to extend the long stop date for the execution of the definitive agreements in relation to the Proposed Investment to 31 December 2018; and
 - (b) to acknowledge that as a result of the extension of the MOU, for the purposes of the First Loan, the Target will be required to repay the First Loan, together with all accrued interest, within nine (9) months of the last drawdown date if the definitive agreements in relation to the Proposed Investment are not executed by 31 December 2018.

2. FURTHER ANNOUNCEMENTS

The Company is currently still in discussions with the relevant parties and there is no definitive agreement in relation to the Proposed Investment at this stage. The Company will make further announcements to keep shareholders informed upon execution of the definitive agreements or as and when there are further material updates and developments in respect of the Proposed Investment.

3. CAUTIONARY STATEMENT

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. In particular, shareholders and potential investors should note that the Proposed Investment is subject to the execution of definitive agreements. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors or other professional advisers.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

13 November 2018

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*